Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEG-Intron [peginterferon alfa-2b]/REBETOL [ribavirin] vs PEGIntron/SCH 503034 [boceprevir] with and without ribavirin in chronic hepatitis C HCV [hepatitis C virus]-1 peginterferon alfa/ribavirin null responders: a SCH 503034 dose-finding phase 2 study.

Next Previous
Trial Profile

PEG-Intron [peginterferon alfa-2b]/REBETOL [ribavirin] vs PEGIntron/SCH 503034 [boceprevir] with and without ribavirin in chronic hepatitis C HCV [hepatitis C virus]-1 peginterferon alfa/ribavirin null responders: a SCH 503034 dose-finding phase 2 study.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms RESPOND 1
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 22 May 2008 Results were reported at the Digestive Disease Week 2008.
    • 15 May 2008 Results reported at DDW 2008, according to a Schering-Plough media release (oral presentation 162; abstract 442360).
    • 17 Apr 2008 Final results will be presented at the European Association for the Study of the Liver 43rd annual meeting in April 2008.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top